NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis $1.42 +0.02 (+1.06%) As of 10:01 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ProQR Therapeutics Stock (NASDAQ:PRQR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProQR Therapeutics alerts:Sign Up Key Stats Today's Range$1.41▼$1.4550-Day Range$1.24▼$2.4352-Week Range$1.20▼$2.81Volume342,135 shsAverage Volume751,598 shsMarket Capitalization$150.14 millionP/E RatioN/ADividend YieldN/APrice Target$7.60Consensus RatingModerate Buy Company Overview ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA. ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas. Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR serves the global biotechnology and pharmaceutical markets through its research, development and strategic collaborations. The company was founded by Daniel de Boer, who has served as its chief executive officer and has led its efforts to develop RNA-based medicines.AI Generated. May Contain Errors. Read More ProQR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScorePRQR MarketRank™: 3.29890251775 of 5 starsProQR Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 334th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingProQR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialProQR Therapeutics has a consensus price target of $7.60, representing about 439.0% upside from its current price of $1.41.Amount of Analyst CoverageProQR Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ProQR Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.45) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ProQR Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.01% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 3.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently increased by 1.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.91 News SentimentProQR Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ProQR Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PRQR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by Institutions32.65% of the stock of ProQR Therapeutics is held by institutions.Read more about ProQR Therapeutics' insider trading history. Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRQR Stock News HeadlinesProQR Therapeutics (PRQR) Set to Post Quarterly Earnings on ThursdayOctober 29 at 3:26 AM | americanbankingnews.comProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesOctober 28 at 8:00 AM | globenewswire.comThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former hedge fund trader Lance Ippolito says it identifies early moves and lets traders set their own risk level instead of guessing.October 29 at 1:00 AM | The TradingPub (Ad)Financial Comparison: ProQR Therapeutics (NASDAQ:PRQR) & aTyr Pharma (NASDAQ:ATYR)October 20, 2026 | americanbankingnews.comProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Average Target Price of $7.60October 18, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)October 2, 2026 | theglobeandmail.comProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorSeptember 23, 2026 | globenewswire.comProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease TreatmentSeptember 10, 2026 | finance.yahoo.comSee More Headlines PRQR Stock Analysis - Frequently Asked Questions How have PRQR shares performed this year? ProQR Therapeutics' stock was trading at $2.02 at the beginning of the year. Since then, PRQR stock has decreased by 30.2% and is now trading at $1.41. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics N.V. (NASDAQ:PRQR) posted its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.04. The biopharmaceutical company had revenue of $10.00 million for the quarter, compared to analyst estimates of $4.56 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 73.83% and a negative net margin of 223.51%. When did ProQR Therapeutics IPO? ProQR Therapeutics (PRQR) raised $90 million in an IPO on Thursday, September 18th 2014. The company issued 7,500,000 shares at $11.00-$13.00 per share. How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProQR Therapeutics investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Solid Biosciences (SLDB), NIO (NIO), Aldeyra Therapeutics (ALDX), Micron Technology (MU) and 9 Meters Biopharma (NMTR). Company Calendar Last Earnings8/13/2026Today10/29/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, PRQR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRQR CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees166Year Founded2012Price Target and Rating Average Price Target for ProQR Therapeutics$7.60 High Price Target$10.00 Low Price Target$3.00 Potential Upside/Downside+439.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.73 million Net Margins-223.51% Pretax Margin-229.40% Return on Equity-73.83% Return on Assets-35.14% Debt Debt-to-Equity RatioN/A Current Ratio3.49 Quick Ratio3.49 Sales & Book Value Annual Sales$17.99 million Price / Sales8.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book2.66Miscellaneous Outstanding Shares105,360,000Free Float96,513,000Market Cap$148.56 million OptionableOptionable Beta0.20 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PRQR) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredThe cash in your checking account has a problemThere's a pile of cash sitting in your checking account, earning next to nothing while you weigh your options....Counterflow | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
